Bio-Techne Licenses AI-Designed NovoBody™ Duo Molecules from Monod Bio to Expand Recombinant Protein Portfolio

Core Insights - Bio-Techne Corporation has entered into a licensing agreement with Monod Bio, granting exclusive commercial rights to a subset of Monod's NovoBody™ Duo molecules, which are AI-designed bispecific binding proteins [1][2] - This partnership aims to enhance scientific progress through innovative AI-powered designs, improving customization, stability, and performance for better therapeutic development [2] - The collaboration aligns with Bio-Techne's strategic growth initiatives and reinforces its position in AI-enabled innovation, a significant trend in global healthcare transformation [2][5] Company Overview: Bio-Techne - Bio-Techne is a global life sciences company that provides innovative tools and bioactive reagents for research and clinical diagnostics, generating over $1.2 billion in net sales in fiscal 2025 [3] - The company employs approximately 3,100 individuals worldwide and offers a vast portfolio of products to assist in scientific investigations and drug discovery [3] Company Overview: Monod Bio - Monod Bio is a Seattle-based biotechnology company that specializes in AI-powered protein design, creating novel protein binders and biosensors for research and diagnostic applications [4] - The company operates under a "Monod Inside" business model, partnering with leading organizations to bring next-generation products to market [4]